March 4, 2026 7:52pm

Better informed than sorry, hedge exposure, always have options

Remember the quote, “War with Iran has ‘only just begun” Def Sec Hegseth

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions as I am more frequently right than consequentially wrong; I am mostly EARLY in my prognostications!

NO pre-open published, was written but computer/provider problems

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

Wednesday: The Dow closed up +238.14 points or +0.49%, the S&P closed UP +52.87 points or +0.78% while the Nasdaq closed UP +290.793 points or +1.29%

·         Theme of the session: gains in tech stocks salved wounds

Wednesday’s (my) 40-company covered sector’s advance/decline line opened positive with 25 incliners, 13 decliners and 2 flats, ending with a positive close of 32 incliners, 6 decliners and 2 flats

Henry’omics: We need to more than consider the macro-economic environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • ADP reported: Companies added 63,000 workers in February, an improvement from the downwardly revised 11,000 in January and better than the consensus estimate for 48,000. Most of the hiring came in just two sectors: health services and construction. Job growth in other sectors either was flat or lower. Pay grew 4.5% for those staying in their jobs while wage gains for job switchers moved down to 6.3%, the smallest gap since ADP began tracking the metric.  

The CBOE Fear (VIX) index, Wednesday closed at 21.15, after Tuesday’s 23.72, Monday’s 21.42, Friday’s 19.90, Thursday’s 18.62 and last Wednesday’s 17.89

Metrics: Wednesday …

·         The RUT was up +27.66 points or +1.06%,

·         The XLV was up +0.32 points or +0.20%,

·         The NBI was up +92.65 points or +1.58%;

·         The XBI was up +2.92 points or +2.36%

·         The IWM was up +2.52 or +0.97%;

·         The IBB was up +2.87 points or +1.69%,

·         The VIX was down -2.42 points or -10.27% at to 21.15

 

Q1/26 – March – 1 positive and 2 negative close

·         February – 1 holiday, 8 negative and 11 positive sessions

·         January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

Q4/25 …

·         December – 1 holiday, 8 positive and 14 negative closes

·         November – 1 holiday, 8 positive and 11 negative closes

·         October -1 neutral, 11 positive and 12 negative closes

 

Wednesday Closing UP (10 of 32) 

  • Alnylam Pharmaceuticals (ALNY +$8.65 after Tuesday’s -$6.42 after Monday’s -$7.85),
  • Moderna (MRNA +$7.97),
  • IQAI Holdings (IQV +$3.92),
  • Vertex (VRTX +$3.62 after Tuesday’s -$11.76 after Monday’s -$10.80),
  • BioNTech (BNTX +$3.04 after Tuesday’s -$6.72 after Monday’s -$2.75),
  • CRISPR Therapeutics (CRSP +$1.94 after Tuesday’s -$2.71 after Monday’s +$0.63),
  • Supernus Therapeutics (SUPN +$1.02),
  • Arrowhead Pharmaceuticals (ARWR +$1.00),
  • Ionis Pharmaceuticals (IONS +$0.79 after Tuesday’s -$3.30 after Monday’s +$0.81),
  • Entrada Therapeutics (TRDA +$0.65),

Flat (2)

  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus RT (OTCQB: HRGN)

Wednesday’s Closing DOWN (6 of 6): 

  • AxoGen (AXGN -$0.61),
  • Capricor Therapeutics (CAPR -$0.34),
  • Ultragenyx Pharmaceuticals (RARE -$0.27),
  • Lenz Therapeutics (LENZ -$0.19),
  • Prime Medicine (PRME -$0.11),
  • Brainstorm Cell Therapeutics (BCLI -$0.01 after Tuesday’s $0.00),

 

The Bottom Line: More of the … WHY

An UP today, better than other sessions …

After 2 volatile sessions, investors scooped up technology stocks that sold off heavily in February.

Moves across all markets continue to be driven by conflict in the Middle East, as attacks between the US, Israel and Iran have spread across the region.

Thursday will mark the 6th day of violence. 

 

Earnings release dates: soon to be catching up

·         Tuesday - 2/24 – AxoGen (AXGN), Beam Therapeutics (BEAM) and Supernus Therapeutics (SUPN)

·         Wednesday – 2/25 – MiMedx (MDXG), Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT)

·         Thursday – 2/26 – Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Wave Life Sciences (WVE), Vericel (VCEL) and BioLife Solutions (BLFS)

·         Monday - 3/2 – Dyne Therapeutics (DYN)

 

RISK is always a factor remaining below the surface …  boiled-up as slight shocks of profiteering on upsides shook but not rocked the C&GT sector and markets!

·         As I had also written, cash is king for investors who want to keep some liquidity and avoid having to sell in a down market,

 

March – 1st week

·         3 /4 – Wednesday closed positive with 32 incliners, 6 decliners and 2 flats

·         3/3 - Tuesday closed negative with 2 incliners, 36 decliners and 2 flats

·         3/2 - Monday closed negative with 15 incliners, 23 decliners and 3 flats

February – 4th week

·         2/27 – Friday closed negative with 12 incliners, 26 decliners and 2 flats

·         2/26 – Thursday closed positive with 24 incliners, 14 decliners and 2 flats

·         2/25 - Wednesday closed positive with 20 incliners, 19 decliners and 1 flat

·         2/24 - Tuesday closed positive with 32 incliners, 5 decliners and 3 flats

·         2/23 - Monday closed positive with 24 incliners, 13 decliners and 3 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

·         Wednesday: Alnylam Pharmaceuticals (ALNY), Moderna (MRNA) and IQIA Holdings (IQV)

·         Tuesday: IQIA Holdings (IQV) and Entrada Therapeutics (TRDA)

·         Monday: Intellia Therapeutics (NTLA), Arrowhead Pharmaceuticals (ARWR) and Ionis Pharmaceuticals (IONS)

The worst three (3) in the session: Losers

·         Wednesday: AxoGen (AXGN), Capricor Therapeutics (CAPR) and Ultragenyx Pharmaceuticals (RARE)

·         Tuesday: Vertex (VRTX), BioNTech (BNTX) and Alnylam Pharmaceuticals (ALNY)

·         Monday: Vertex (VRTX), uniQure NV (QURE) and IQIA Holdings (IQV)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.